Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential of T-DM1 as monotherapy is so far unknown. OBJECTIVE: To assess pathologic complete response (pCR) to standard neoadjuvant t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Hatschek, Thomas, Foukakis, Theodoros, Bjöhle, Judith, Lekberg, Tobias, Fredholm, Hanna, Elinder, Ellinor, Bosch, Ana, Pekar, Gyula, Lindman, Henrik, Schiza, Aglaia, Einbeigi, Zakaria, Adra, Jamila, Andersson, Anne, Carlsson, Lena, Dreifaldt, Ann Charlotte, Isaksson-Friman, Erika, Agartz, Susanne, Azavedo, Edward, Grybäck, Per, Hellström, Mats, Johansson, Hemming, Maes, Claudia, Zerdes, Ioannis, Hartman, Johan, Brandberg, Yvonne, Bergh, Jonas
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227457/
https://ncbi.nlm.nih.gov/pubmed/34165503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.1932
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados